Angioid Streaks Treatment & Management
- Author: Mohammad Abusamak, MD; Chief Editor: Hampton Roy, Sr, MD more...
Initially, patients are asymptomatic and no indication for prophylactic treatment is present. Angioid streaks are a generalized disorder of the Bruch membrane.
Angioid streaks are an uncommon entity to be studied and are treated as part of a controlled and randomized study. Treatment methods are based mainly on individual experience and extrapolation from the Macular Photocoagulation Study Group. Patients with angioid streaks are at higher risk of choroidal rupture and subretinal hemorrhage secondary to mild blunt trauma. They are advised to wear protective goggles and sports glasses when playing sports and during work.
Treatment options include observation, laser photocoagulation, and surgical removal of CNVM under the fovea. The Food and Drug Administration (FDA) approved the use of photodynamic therapy (PDT) for CNVM secondary to age-related macular degeneration (ARMD).
- Initially, symptomatic patients complained of a decrease in their central visual acuity, and some developed distortion and metamorphopsia that was more disturbing than the associated central scotomas. Usually, central scotomas tend to increase in size if left untreated before subsequent scarring of the macula occurs.
- Early at the time of diagnosis, more than 50% of patients had vision of 20/40 or better; one half of them became legally blind at an average follow-up period of 3.5 years. Most eyes had vision 20/200 or worse after age 50 years.
- In one study, 11 untreated eyes with subretinal neovascular membranes all had a final visual acuity of counting fingers. Clarkson and Altman reported 29 patients seen on 2 occasions over a period of at least 6 months. Decreased vision of 2 lines or greater on the Snellen chart occurred in 13 of 29 patients.
- Prophylactic laser treatment in clinically asymptomatic eyes without active choroidal neovascularization is not recommended. In one study, prophylactic treatment was associated with an increased incidence of neovascularization at the site of treatment. However, patients who received laser photocoagulation noticed a decrease in the size of their central scotomas and early relief from visual distortion.
- Photocoagulation, including light (xenon) and argon, has been used since the early 1970s, although angioid streaks themselves were treated to stop their progression toward the macula. Early treatment experiences with light and laser photocoagulation were disappointing and discouraging. Some investigators discouraged laser treatment of CNVM in angioid streaks.
- Some success with argon laser for lesions that are located at least 100 µm from the center of the foveal avascular zone (FAZ) has been reported.
- Laser therapy is believed to slow the progression of the CNV toward the fovea and stabilizes vision. Moreover, it improves the quality of vision (ie, size of central scotoma, decreases metamorphopsia). Successful treatment of CNV may not improve central vision in some patients since dehiscences in the Bruch membranes may involve and damage the foveal RPE.
- Many investigators found that laser treatment, if administered early and adequately to CNV lesions, may have a favorable result on long-term visual outcome.
- Many patients needed multiple treatments because of persistent leakage and recurrence that occurred during the first 3 months.
- Patients need to be monitored closely with Amsler grids and FA.
- In several series, the recurrence rate was reported as high as 77% of patients who underwent laser treatment. Most recurrent CNVMs were subfoveal. The incidence of recurrence was higher in angioid streaks than in other conditions, such as ARMD, degenerative myopia, and histoplasmosis.
- Treating CNVM associated with angioid streaks is sometimes challenging. Both occult and classic CNV can occur in the same eye and usually are located very close to the foveal avascular zone. RPE reaction is minimal around CNVM. Some of these membranes grow fast once they break through the Bruch membrane. Careful setup of laser power and spot size is important to prevent further damage to the brittle and mineralized Bruch membrane.
- PDT is a modality approved by the FDA for the treatment of CNV secondary to ARMD. It uses a light activated drug (eg, verteporfin [Visudyne]) and applying a nonthermal red light in the range of 689 nanometers. The total energy delivered is 50 J/cm2 over a period of 83 seconds. The power of laser output can be adjusted according to size of CNV and ophthalmic lens magnification.
- A study evaluated the short-term safety and visual effects after administering PDT in 13 patients with classic subfoveal CNV secondary to pathological myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes. Most patients gained at least 1 line of vision. Reduction in the size of leakage area from classic CNV was noted in all patients as early as 1-week posttreatment, with complete absence of leakage in almost one half of the patients. Up to 4 treatments were found to have short-term safety even with re-treatment intervals as short as 4 weeks.
- Karacorlu et al evaluated the safety and efficacy of PDT with verteporfin for subfoveal CNV associated with angioid streaks in 8 eyes and showed that PDT generally achieved a short-term cessation of or a decrease of fluorescein leakage from subfoveal CNVM without loss of vision in patients with angioid steaks.
- Long-term effects of PDT, especially in patients who may need multiple treatments, are unknown. Patients with angioid streaks are at higher risk of recurrent CNV.
Right eye, midphase arteriovenous, showing choriocapillaris atrophic changes. This 45-year-old patient underwent 3 injections of Avastin and one session of half-time photodynamic therapy.
- Recently, with the advent of antivascular endothelial antibodies, namely bevacizumab and ranibizumab, the treatment of choroidal neovascularization secondary to angioid streak has taken a great positive turn. Many patients are treated with anti–vascular endothelial growth factor (VEGF) therapy worldwide. The visual function showed stabilization over extended periods. Unfortunately, the recurrence rate is high and many patients need repeated injections to control the disease.[12, 13, 14, 15]
- Combination low-fluence photodynamic therapy and ranibizumab were used successfully to treat cases of angioid streaks in many centers around the world.[16, 17]
See the list below:
- Patients with classic subfoveal CNVM are not candidates for laser photocoagulation therapy. In the past, they were left without treatment. However, advances in instrumentation and vitreoretinal surgical techniques have made it possible to remove CNVM without significant damage to RPE and neurosensory retina.
- Eckstein et al reported encouraging short-term visual results in 31 consecutive patients with non–age-related subfoveal CNVM, including angioid streaks. Visual acuity improved or remained the same in 25 of 31 eyes. Moreover, visual acuity improved by more than 2 lines in 5 eyes (16%). Older patients and those with atrophic RPE had the worst outcome. Recurrent CNV occurred in 11 eyes (35%). The presence of subfoveal blood was associated with a higher recurrence rate of membranes. There was no significant association between the final visual acuity and length of symptoms prior to surgery or preoperative vision.
Patients with angioid streaks have a high risk of choroidal rupture and subretinal hemorrhage secondary to mild blunt trauma. It is recommended that patients wear protective sports glasses whenever applicable.
Doyne RW. Choroidal and retinal changes. The result of blows on the eyes. Trans Ophthal. 1889. 9:128.
Knapp H. On the formation of dark angioid streaks as an unusual metamorphosis of retinal hemorrhage. Arch Ophthalmol. 1892. 21:289-292.
Klien BA. Angioid Streaks: A clinical and histopathologic study. American Journal of Ophthalmology. 1947. 30:955-68.
Abujamra S, Negretto AD, Saraceno JJ, Oliveira TL, Gomes AM. [Angioid streaks: fundoscopic analysis of 317 cases]. Arq Bras Oftalmol. 2008 Nov-Dec. 71(6):819-21. [Medline].
Mansour AM, Ansari NH, Shields JA, Annesley WH Jr, Cronin CM, Stock EL. Evolution of angioid streaks. Ophthalmologica. 1993. 207(2):57-61. [Medline].
Dhermy P. Histologie Angioid Streaks. Cosca G, Soubane G, eds. Neovasseaux Sous-Retiniens et Laser. Paris, France: 1987. 210-1.
Gass J, Donald M. Stereoscopic Atlas of Macular Diseases: Diagnosis and Treatment. 4th ed. CV Mosby: 1997. Vol. 1: 120.
Piro PA, Scheraga D, Fine S. Angioid Streaks: Natural history and visual prognosis. Management of Retinal Vascular and Macular Disorders. Williams and Wilkins; 1983. 136-9.
Clarkson JG, Altman RD. Angioid streaks. Surv Ophthalmol. 1982 Mar-Apr. 26(5):235-46. [Medline].
Karacorlu M, Karacorlu S, Ozdemir H, et al. Photodynamic therapy with verteporfin for choroidal neovascularization in patients with angioid streaks. Am J Ophthalmol. 2002 Sep. 134(3):360-6. [Medline].
Sawa M, Gomi F, Tsujikawa M, Sakaguchi H, Tano Y. Long-term results of intravitreal bevacizumab injection for choroidal neovascularization secondary to angioid streaks. Am J Ophthalmol. 2009 Oct. 148(4):584-590.e2. [Medline].
Neri P, Salvolini S, Mariotti C, Mercanti L, Celani S, Giovannini A. Long-term control of choroidal neovascularisation secondary to angioid streaks treated with intravitreal bevacizumab (Avastin). Br J Ophthalmol. 2009 Feb. 93(2):155-8. [Medline].
Finger RP, Charbel Issa P, Hendig D, Scholl HP, Holz FG. Monthly Ranibizumab for Choroidal Neovascularizations Secondary to Angioid Streaks in Pseudoxanthoma Elasticum: A One-Year Prospective Study. Am J Ophthalmol. 2011 Jun 24. [Medline].
Gliem M, Finger RP, Fimmers R, Brinkmann CK, Holz FG, Charbel Issa P. Treatment of choroidal neovascularization due to angioid streaks: a comprehensive review. Retina. 2013 Jul-Aug. 33(7):1300-14. [Medline].
Prabhu VV, Morris RJ, Shah PK, Narendran V. Combination treatment of low fluence photodynamic therapy and intravitreal ranibizumab for choroidal neovascular membrane secondary to angioid streaks in Paget's disease - 12 month results. Indian J Ophthalmol. 2011 Jul-Aug. 59(4):306-8. [Medline]. [Full Text].
Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Senel A, Bahcecioglu H. Combination treatment with intravitreal injection of ranibizumab and reduced-fluence photodynamic therapy for choroidal neovascularization secondary to angioid streaks: Preliminary Clinical Results of 12-Month Follow-Up. Retina. 2011 Jul-Aug. 31(7):1279-86. [Medline].
Eckstein M, Wells JA, Aylward B, Gregor Z, et al. Surgical removal of non-age-related subfoveal choroidal neovascular membranes. Eye. 1998. 12 (Pt 5):775-80. [Medline].
Adelung JC. Zur Geneseder angioid streaks (Knapp). Klin Monatsbl Augenheilkd. 1951. 119:241.
Aveline B, Hasan T, Redmond RW. Photophysical and photosensitizing properties of benzoporphyrin derivative monoacid ring A (BPD-MA). Photochem Photobiol. 1994 Mar. 59(3):328-35. [Medline].
Bock J. Zur Klinik und Anatomic der gefaessehnlichen Streifen in Augenhintergrund. Z Augenheilkd. 1938. 95:1-50.
Eretto P, Krohel GB, Shihab ZM, et al. Optic neuropathy in Paget's disease. Am J Ophthalmol. 1984 Apr. 97(4):505-10. [Medline].
Francois J, De Laey JJ, Cambie E, et al. Neovascularization after argon laser photocoagulation of macular lesions. Am J Ophthalmol. 1975 Feb. 79(2):206-10. [Medline].
Gelisken O, Hendrikse F, Deutman AF. A long-term follow-up study of laser coagulation of neovascular membranes in angioid streaks. Am J Ophthalmol. 1988 Mar 15. 105(3):299-303. [Medline].
Guyer DR, Gragoudas ES, D'Amico DJ. Chapter 66: Angioid Streaks. Principles and Practice of Ophthalmology. 1993. Vol. 2: 852-60.
Hagedoorn A. Angioid streaks. Arch Ophthalmol. 1939. 21:746-74.
Heimann H, Gelisken F, Wachtlin J, et al. Photodynamic therapy with verteporfin for choroidal neovascularization associated with angioid streaks. Graefes Arch Clin Exp Ophthalmol. 2005 Nov. 243(11):1115-23. [Medline].
Ladas ID, Georgalas I, Rouvas AA, et al. Photodynamic therapy with verteporfin of choroidal neovascularization in angioid streaks: conventional versus early retreatment. Eur J Ophthalmol. 2005 Jan-Feb. 15(1):69-73. [Medline].
Lafaut BA, Leys AM, Scassellati-Sforzolini B, et al. Comparison of fluorescein and indocyanine green angiography in angioid streaks. Graefes Arch Clin Exp Ophthalmol. 1998 May. 236(5):346-53. [Medline].
Macular Photocoagulation Study. Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Macular Photocoagulation Study Group. Arch Ophthalmol. 1990 Jun. 108(6):825-31. [Medline].
Macular Photocoagulation Study Group. Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis. Macular Photocoagulation Study Group. Arch Ophthalmol. 1989 Mar. 107(3):344-52. [Medline].
Meislik J, Neldner K, Reeve EB, et al. Laser treatment in maculopathy of pseudoxanthoma elasticum. Can J Ophthalmol. 1978 Jul. 13(3):210-12. [Medline].
Miller H, Miller B, Ryan SJ. Correlation of choroidal subretinal neovascularization with fluorescein angiography. Am J Ophthalmol. 1985 Mar 15. 99(3):263-71. [Medline].
Pece A, Avanza P, Introini U, et al. Indocyanine green angiography in angioid streaks. Acta Ophthalmol Scand. 1997 Jun. 75(3):261-5. [Medline].
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol. 1999 Oct. 117(10):1329-45. [Medline].
Pierro L, Brancato R, Minicucci M, et al. Echographic diagnosis of Drusen of the optic nerve head in patients with angioid streaks. Ophthalmologica. 1994. 208(5):239-42. [Medline].
Reinke MH, Canakis C, Husain D, et al. Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey. Ophthalmology. 1999 Oct. 106(10):1915-23. [Medline].
Schmidt-Erfurth U, Hasan T, Gragoudas E, et al. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology. 1994 Dec. 101(12):1953-61. [Medline].
Scott LJ, Goa KL. Verteporfin. Drugs Aging. 2000 Feb. 16(2):139-46; discussion 147-8. [Medline].
Shields JA, Federman JL, Tomer TL, Annesley WH Jr. Angioid streaks. I. Ophthalmoscopic variations and diagnostic problems. Br J Ophthalmol. 1975 May. 59(5):257-66. [Medline].
Sickenberg M, Schmidt-Erfurth U, Miller JW, et al. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes. Arch Ophthalmol. 2000 Mar. 118(3):327-36. [Medline].
Singerman LJ, Hatem G. Laser treatment of choroidal neovascular membranes in angioid streaks. Retina. 1981. 1(2):75-83. [Medline].
Walker ER, Frederickson RG, Mayes MD. The mineralization of elastic fibers and alterations of extracellular matrix in pseudoxanthoma elasticum. Ultrastructure, immunocytochemistry, and X-ray analysis. Arch Dermatol. 1989 Jan. 125(1):70-6. [Medline].